Ionis’ HAE Opportunity Boosted By Positive Phase II Data
Wholly Owned PKK-LRx HAE Candidate Hit All Endpoints
Executive Summary
Positive topline Phase II data for Ionis’ antisense hereditary angioedema candidate has boosted the biotech’s chances of developing PKK-LRx as a treatment for the disease.
You may also be interested in...
Pharming And Orchard Seek Stem Cell Solution To Hereditary Angioedema
Orchard Therapeutics of the US and Dutch biotech Pharming have agreed to jointly research, develop, manufacture and commercialize the former’s newly disclosed investigational ex vivo autologous hematopoietic stem cell gene therapy as a treatment for hereditary angioedema.
Roche Shelves Phase III Huntington's Candidate Tominersen
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
KalVista Reports Positive Phase II Data For Oral HAE Attack Therapy KVD900
The company sees KVD900 as potentially “ideal” for patients using on-demand and prophylactic therapy, given the existing need to carry backup on-demand medications.